SYRE
Spyre Therapeutics, Inc.Company Information
- Company Name
- Spyre Therapeutics, Inc.
- CIK
- CIK0001636282
- Category
- Large accelerated filer
- Ticker: Exchange
- SYRE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SYRE
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-02
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 5,184,799
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 93,365,742
- Shares outstanding
- 346,045
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- -13.89%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonrelated Party | 0 | 6 | 9 | 4 | 0 | 4 | 1 | - | - | - | 1 | - | ||||||
| Related Party | 0 | 6 | 9 | 4 | 0 | 4 | 1 | 11 | -11 | 22 | 1 | - | ||||||
| Series A Non Voting Convertible Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | ||||||
| Preferred Stock Excluding Series A Non Voting Convertible Preferred Stock | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | - | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | 0.00 | - | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Series B Non Voting Convertible Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | - | ||||||
Stockholders Equity Number Of Shares Par Value And Other Disclosures | ||||||||||||||||||
| Preferred Stock Excluding Series A And B Non Voting Convertible Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | 10 | - | - | - | 10 | - | - | 9 | 10 | 9 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | 0 | - | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | 0 | - | 0 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 162 | 97 | 86 | 65 | 82 | 48 | 89 | 72 | 45 | 228 | 189 | 91 | ||||||
| Available For Sale Securities Debt Securities Current | 983 | 644 | 671 | 421 | 445 | 516 | 514 | 343 | 381 | 257 | 150 | 113 | ||||||
| Nontrade Receivables Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 28 | 22 | 21 | 18 | 12 | 5 | 5 | 7 | 10 | 3 | 2 | 2 | ||||||
| Assets Current | 1,173 | 764 | 778 | 505 | 539 | 570 | 608 | 421 | 436 | 487 | 342 | 206 | ||||||
| Other Assets Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Noncurrent | - | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets | 1,173 | 764 | 778 | 505 | 539 | 570 | 608 | 421 | 436 | 488 | 342 | 207 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Trade Current | - | - | - | - | - | - | - | 5 | 3 | 3 | 1 | 2 | ||||||
| Derivative Liabilities Current | 31 | 50 | 23 | 11 | 60 | 43 | 25 | 25 | 3 | 3 | 1 | 8 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Accrued Liabilities And Other Liabilities | 26 | 29 | 27 | 24 | 19 | 22 | 28 | 13 | 6 | 22 | 13 | 16 | ||||||
| Accounts Payable Other Current | - | - | - | - | - | - | - | - | - | 16 | 17 | 20 | ||||||
| Liabilities Current | 63 | 85 | 59 | 46 | 83 | 71 | 54 | 58 | 22 | 43 | 32 | 45 | ||||||
| Derivative Liabilities Noncurrent | 7 | 7 | 4 | 3 | 0 | 16 | 37 | 36 | 40 | 39 | 41 | 21 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 72 | 93 | 63 | 50 | 83 | 87 | 91 | 94 | 62 | 82 | 73 | 66 | ||||||
| Preferred Stock Value | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | 0 | - | - | - | 85 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 2,190 | 1,712 | 1,686 | 1,364 | 1,353 | 1,343 | 1,334 | 1,086 | 1,066 | 776 | 763 | 456 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -1 | 1 | 1 | 0 | 1 | 0 | 1 | -1 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,233 | -1,197 | -1,128 | -1,065 | -1,054 | -1,017 | -972 | -916 | -847 | -808 | -764 | -701 | ||||||
| Stockholders Equity | 1,101 | 671 | 715 | 455 | 456 | 483 | 518 | 327 | 374 | 152 | 184 | -245 | ||||||
| Liabilities And Stockholders Equity | 1,173 | 764 | 778 | 505 | 539 | 570 | 608 | 421 | 436 | 488 | 342 | 207 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 20 | ||||||
| Common Stock Shares Issued | 88 | 79 | 78 | 60 | 60 | 60 | 60 | 51 | 51 | 37 | 36 | 4 | ||||||
| Shares Outstanding | 88 | 79 | 78 | 60 | 60 | 60 | 60 | 51 | 51 | 37 | 36 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSpyre Therapeutics, Inc. (SYRE) — SEC Financial Statements & Analysis
Spyre Therapeutics, Inc. (SYRE) is a pharmaceutical preparations company, incorporated in DE. Spyre Therapeutics, Inc. trades on Nasdaq as: SYRE. Spyre Therapeutics, Inc. (SYRE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Spyre Therapeutics, Inc. carries a market cap of $30.72M, a P/E ratio of -0.17x, a P/B ratio of 0.03x, a P/S ratio of 2012.97x, an enterprise value of $-131.29M, and an EV/EBITDA multiple of 0.65x. On profitability, it posts an operating margin of -39428.92%, a net margin of -52939.68%, a Return on Equity (ROE) of -22.98%, a Return on Assets (ROA) of -20.90%, and a Return on Invested Capital (ROIC) of -30.66%. Per share, it reports EPS of $-517.04, diluted EPS of $-517.04, free cash flow per share of $-603.81, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -13.49% year-over-year, and EPS growth of -13.49% year-over-year. On the balance sheet, it maintains a current ratio of 18.53x, a quick ratio of 18.09x, working capital of $1.11B, a debt-to-equity ratio of 0.07x, a debt ratio of 0.06, free cash flow of $-208.94M (TTM), and net debt of $-162.01M. Figures sourced from SEC EDGAR.
- Market Cap
- $30.72M
- P/E TTM
- -0.17x
- EPS TTM
- $-517.04
- P/B TTM
- 0.03x
- ROE TTM
- -22.98%
- ROA TTM
- -20.90%
- Debt To Equity
- 0.07x
- Free Cash Flow TTM
- $-208.94M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Spyre Therapeutics, Inc. in?
Spyre Therapeutics, Inc. (SYRE) operates in the Pharmaceutical Preparations industry.
What exchange does SYRE trade on?
Spyre Therapeutics, Inc. (SYRE) trades on the Nasdaq.
Where is Spyre Therapeutics, Inc. incorporated?
Spyre Therapeutics, Inc. is incorporated in DE.
When was Spyre Therapeutics, Inc. (SYRE)'s most recent SEC filing?
Spyre Therapeutics, Inc. (SYRE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is SYRE's market cap?
Spyre Therapeutics, Inc. (SYRE) has a market capitalization of $30.72M as of 2026-06-30.
What is SYRE's EPS (earnings per share)?
Spyre Therapeutics, Inc. (SYRE)'s trailing twelve month EPS is $-517.04 as of 2026-06-30.
What is SYRE's ROE (return on equity)?
Spyre Therapeutics, Inc. (SYRE)'s trailing twelve month Return on Equity (ROE) is -22.98% as of 2026-06-30.
What is SYRE's ROA (return on assets)?
Spyre Therapeutics, Inc. (SYRE)'s trailing twelve month Return on Assets (ROA) is -20.90% as of 2026-06-30.
What is SYRE's ROIC (return on invested capital)?
Spyre Therapeutics, Inc. (SYRE)'s trailing twelve month Return on Invested Capital (ROIC) is -30.66% as of 2026-06-30.
What is SYRE's EV/EBITDA?
Spyre Therapeutics, Inc. (SYRE)'s trailing twelve month EV/EBITDA is 0.65x as of 2026-06-30.